A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
Soria, J.C., Gan, H.K., Blagden, S.P., Plummer, R., Arkenau, H.T., Ranson, M., Evans, T.R.J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., Auger, K.R., Fleming, R.A., Singh, R., Millward, M.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Hertzberg, M., Kalac, M., Cheah, C. Y., Ribrag, V., Abrisqueta, P., Opat, S., Bachy, E., Ysebaert, L., Qiu, L., Yi, S., Nishimura, N., Lemech, C., Bussolari, J., Deng, C., Lu, T., Xiu, L., Hemelryck, S. V., Philippar, U., Guo, Y., Soete, V., Paradinas, I. S., Fourneau, N., Gerecitano, J., Morschhauser, F.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors
Coward, J., Lemech, C., Meniawy, T., Dupont, C.D., Gonzalez, A.M., Lim, M., Savitsky, D., Carini, M., Hu, S., Shebanova, O., Dow, E., Ortuzar, W., Buell, J.S., Stein, R.B., Youssoufian, H.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Weickhardt, A.J., Frentzas, S., Lemech, C., Srimani, J., Yin, J., Trepicchio, W.L., Gorgun, C., Kichenadasse, G.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Strickler, John H., Satake, Hironaga, George, Thomas J., Yaeger, Rona, Hollebecque, Antoine, Garrido-Laguna, Ignacio, Schuler, Martin, Burns, Timothy F., Coveler, Andrew L., Falchook, Gerald S., Vincent, Mark, Sunakawa, Yu, Dahan, Laetitia, Bajor, David, Rha, Sun-Young, Lemech, Charlotte, Juric, Dejan, Rehn, Marko, Ngarmchamnanrith, Gataree, Jafarinasabian, Pegah, Tran, Qui, Hong, David S.
Published in The New England journal of medicine (05.01.2023)
Published in The New England journal of medicine (05.01.2023)
Get full text
Journal Article
1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors
Tran, B., Millward, M., Lemech, C., Frentzas, S., Day, D., Latifi, A., Desai, J., Wabnitz, P., Kearney, P., Galkin, A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors
Lemech, C., Kichenadasse, G., Teng, C., Nagrial, A., Richardson, G., Humphries, T.G., Killen, A.J., Joshua, A., Liu, J.J., Churchill, M., Barnett, M., Cioffi, M., Cosman, R.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
Lemech, C., Sun, Y., Nagrial, A., Wu, X., Morris, M., Ning, F., Yang, J., Pan, Y., Cai, J., Lu, P., Zhang, T., Qiu, F., Hu, C., Zhang, M., Liu, Z., Han, G., Nie, J., Teng, C., Zhou, H., Day, D.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Gong, J., Lemech, C., Day, D., Shan, J., Morris, M., Nagrial, A., Chen, M., Huang, X., Zong, H., Wang, N., Yang, Y., Yi, T., Li, W., Zhuang, Z., Li, Z., Liu, Z., Luo, Y., Zhang, Y., Zhou, H., Shen, L.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Lemech, C., Luke, J.J., Falchook, G.S., Mckean, M., Kichenadasse, G., Teng, C., Vandross, A.L., Salkeni, M.A., Atkinson, V.G., Liu, J.J., Kennedy, A.M., Clark, J., Ryan, M., Schmidt-Kittler, O., Steinhubel, D., Wages, D., Komarnitsky, P., Puzanov, I.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
Novel Use of Micra AV Pacemaker for Immune Checkpoint Inhibitor-associated Myocarditis, Life-sustaining Ventricular Tachycardia and Atrioventricular Dissociation
Vickers, D., Port, K., Li, J., Eather, S., Cranney, G., Lemech, C., Singarayar, S.
Published in Heart, lung & circulation (01.07.2023)
Published in Heart, lung & circulation (01.07.2023)
Get full text
Journal Article
1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation
Lee, D.H., Roohullah, A., Cho, B.C., Lee, S-H., Lemech, C., de Souza, P., Millward, M., Choi, J., Park, K.E., Kim, E., Kim, N.Y., Shin, Y.K., Han, J-Y.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors
Falchook, G.S., Fu, S., Lemech, C., Mckean, M.A., Azad, A.A., Gan, H.K., Sommerhalder, D., Wang, J.S., Tan, T.J.Y., Chee, C.E., Barve, M., Moser, J., Mooney, J., Acuff, N., Wang, R., Marina, N., Abbadessa, G., Streit, M., Ramusovic, S., Meniawy, T.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1358P Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor
Lee, D.H., Roohullah, A., Cho, B.C., Lemech, C., de Souza, P., Millward, M., Choi, J., Park, K.E., Lee, M., Kim, Y., Park, S., Lee, J., Kim, J., Shin, Y.K., Han, J-Y.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing
Markman, B., Day, D., Park, J.J.W., Coward, J., Bishnoi, S., Kotasek, D., Eek, R., Brown, M.P., Lemech, C., Kuo, J., Prawira, A., Strother, R., Zhang, Q., Wang, L., Chen, R., Ma, Y., Qin, Z., Tse, A.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
Tran, B., Horvath, L., Dorff, T., Rettig, M., Lolkema, M.P., Machiels, J-P., Rottey, S., Autio, K., Greil, R., Adra, N., Lemech, C., Minocha, M., Cheng, F-C., Kouros-Mehr, H., Fizazi, K.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1168PPhase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors
Coward, J, Lemech, C, Meniawy, T, Dupont, C D, Gonzalez, A M, Lim, M, Savitsky, D, Carini, M, Hu, S, Shebanova, O, Dow, E, Ortuzar, W, Buell, J S, Stein, R B, Youssoufian, H
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer
Baird, RD, Cresti, N, Beddowes, E, Saggese, M, Flynn, M, Garcia Corbacho, J, Gao, F, Lemech, C, Donaldson, K, Posner, J, Kawabata, I, Forster, M, Arkenau, HT, Plummer, R, Jodrell, D, Spicer, J
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article